New Cancer Drugs Offers Hope In Mesothelioma Treatment
Written By Jhon Doe on Sunday, November 13, 2011 | 12:17 AM
According to a study published in the “Journal of Thoracic Oncology” 5 issue of a study. a drug that is used to treat kidney cancer may enhance the efficacy of chemotherapy for mesothelioma.
Temsirolimus, a kinase inhibitor, It can blocks the growth of mammalian target of rapamycin (mTOR) proteins. Order to slow tumor growth. The drug for the treatment of advanced renal cell carcinoma. However, the Austrian researchers found that temsirolimus may also slow down the growth of malignant pleural mesothelioma cells. Mesothelioma is a malignant cancer that can start in the cavities of the lungs, the heart, or the abdomen. It is a rare cancer that occurs in the thin layer of tissue that covers the majority of your internal organs (mesothelium). Mesothelioma was found usually in the late, The effects of mesothelioma chemotherapy is disappointing. The researchers found that temsirolimus can strongly block the mTOR-mediated signal and play a role in inhibiting the growth or stop. However, cisplatin, a commonly used chemotherapy drug for mesothelioma treatment, displayed hypersensitivity against temsirolimus. Because of this, researchers in the study believe temsirolimus can be used in combination with other current chemotherapeutic treatments as a second-line treatment. mTOR inhibitors, such as temsirolimus combined with chemotherapy or as a second-line treatment after failure of chemotherapy may be a promising therapeutic strategy.
Malignant mesothelioma is a rare cancer that occurs in the thin layer of tissue that covers the majority of your internal organs (mesothelium). It is a rare tumor, usually occurred in pleura, peritoneum and cardiac pericardium and so on. The majority is malignant, with short surviving period and high mortality. The treatment of malignant pleural mesothelioma, is still no effective cure methods. Pemetrexed disodium is the only agent for the treatment of malignant pleural mesothelioma(MPM). Pemetrexed was initially approved in 2004 for treating patients with. Pemetrexed is a multitargeted antimetabolite that has shown activity in malignant pleural mesothelioma and NSCLC, which has been approved in more than 70 countries.
Posted by Jhon Doe at 12:17 AM